Pacific Biosciences Of California (PACB) Long-Term Debt Issuances (2013 - 2021)
Pacific Biosciences Of California's quarterly Long-Term Debt Issuances came in at -$88000.0 in Q2 2021, down 100.01% quarter-over-quarter from $895.6 million in Q1 2021.
Pacific Biosciences Of California has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$88000.0 in Q2 2021.
- For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to -$88000.0; the trailing twelve-month figure through Dec 2021 stood at $895.5 million (changed N/A YoY), and the FY2021 full-year result was $895.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q2 2021 stood at -$88000.0, down from $895.6 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $895.6 million in Q1 2021, with the low at -$88000.0 in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 19.86 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 11.71 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 1.15 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -88,000.00 |
| Jun 30, 2021 | -88,000.00 |
| Mar 31, 2021 | 895.62 Mn |
| Mar 31, 2021 | 895.62 Mn |
| Mar 31, 2013 | 19.77 Mn |
| Mar 31, 2013 | 19.77 Mn |